EPISODE · Jun 13, 2025 · 1H 10M
EASL DeepDive: MASLD Cirrhosis: Addressing unmet needs and defining valuable endpoints
from EASL Podcasts
In this new edition of the EASL DeepDive, expert faculty guide participants through a focused and forward-looking discussion on key aspects of advanced MASLD, setting the stage for a deeper understanding of evolving clinical challenges and opportunities.This EASL DeepDive webinar is supported by Boehringer Ingelheim. Boehringer Ingelheim has had no input into the content of this EASL DeepDive.Learning objectivesUnderstand the Pathophysiology: Describe the key pathophysiological mechanisms of MASLD and its progression to advanced liver disease and portal hypertension.Identify Unmet Clinical Needs: Recognise the current gaps in diagnosis, management, and treatment of advanced MASLD, highlighting the challenges of healthcare professionals in clinical practice.Evaluate Valuable Endpoints: Discuss the importance of selecting and utilising valuable clinical endpoints in managing MASLD to improve patient outcomes.Explore Emerging Therapies: Review the latest therapeutic strategies and potential interventions for advanced MASLD, focusing on how they address the unmet needs in patient care.All EASL DeepDive are available on EASL Campus.
Embed this episode
What this episode covers
In this new edition of the EASL DeepDive, expert faculty guide participants through a focused and forward-looking discussion on key aspects of advanced MASLD, setting the stage for a deeper understanding of evolving clinical challenges and opportunities. This EASL DeepDive webinar is supported by Boehringer Ingelheim. Boehringer Ingelheim has had no input into the content of this EASL DeepDive. Learning objectives Understand the Pathophysiology: Describe the key pathophysiological mechanisms...
NOW PLAYING
EASL DeepDive: MASLD Cirrhosis: Addressing unmet needs and defining valuable endpoints
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.